Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer-To Treat or Not to Treat.
作者信息
van Velsen Evert F S, Verburg Frederik A
机构信息
Department of Internal Medicine, Erasmus Medical Center, 3015 CE, Rotterdam, The Netherlands.
Academic Center for Thyroid Diseases, Erasmus Medical Center, 3015 CE, Rotterdam, The Netherlands.
出版信息
J Clin Endocrinol Metab. 2023 Sep 18;108(10):e1149-e1150. doi: 10.1210/clinem/dgad171.
Abstract
摘要
相似文献
1
Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer-To Treat or Not to Treat.中危乳头状甲状腺癌的辅助放射性碘治疗——治疗与否
J Clin Endocrinol Metab. 2023 Sep 18;108(10):e1149-e1150. doi: 10.1210/clinem/dgad171.
2
Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?中间风险甲状腺癌患者的治疗反应评估：是否需要促甲状腺球蛋白刺激？
Thyroid. 2020 Jun;30(6):863-870. doi: 10.1089/thy.2019.0431. Epub 2020 Mar 2.
3
Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.1611 例甲状腺乳头状癌患者全甲状腺切除术后复发的预测因素：术后刺激血清甲状腺球蛋白和 ATA 初始及动态风险评估。
Arch Endocrinol Metab. 2024 Apr 4;68:e220506. doi: 10.20945/2359-4292-2022-0506.
4
Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.中危甲状腺乳头状癌：初始治疗有良好反应患者早期复发的危险因素。
Thyroid. 2018 Oct;28(10):1311-1317. doi: 10.1089/thy.2017.0578.
5
Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.放射性碘摄取和甲状腺球蛋白指导下分化型甲状腺癌残余碘消融：一项前瞻性、随机、开放标签、对照试验。
Thyroid. 2019 Jan;29(1):101-110. doi: 10.1089/thy.2018.0028.
6
Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.辅助放射性碘治疗后伴有其他器官侵犯的甲状腺乳头状癌患者的长期临床结局和预后因素。
Endocrine. 2023 Apr;80(1):79-85. doi: 10.1007/s12020-022-03251-0. Epub 2022 Nov 11.
7
Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer.早期术后刺激血清甲状腺球蛋白：在低危和中危甲状腺乳头状癌中预防不必要放射性碘治疗的作用。
Am Surg. 2023 Dec;89(12):5996-6004. doi: 10.1177/00031348231157816. Epub 2023 Jun 13.
8
Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.1850 兆贝克勒尔放射性碘消融联合重组人促甲状腺素用于分化型甲状腺癌患者的治疗
J Endocrinol Invest. 2014 Aug;37(8):709-714. doi: 10.1007/s40618-014-0088-3. Epub 2014 May 21.
9
Impact factors for the outcome of the first I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy.全甲状腺切除术后乳头状甲状腺癌患者首次碘放疗结局的影响因素。
Ann Nucl Med. 2019 Mar;33(3):177-183. doi: 10.1007/s12149-018-01321-w. Epub 2018 Dec 4.
10
Is radioiodine ablation necessary for patients with low-risk papillary thyroid carcinoma and tumor >4 cm?对于低风险乳头状甲状腺癌且肿瘤>4厘米的患者，放射性碘消融是否必要？
Eur J Surg Oncol. 2017 Sep;43(9):1802-1803. doi: 10.1016/j.ejso.2017.05.025. Epub 2017 Jul 18.
引用本文的文献
1
Predictors of distant metastatic recurrence in intermediate-risk papillary thyroid carcinoma.中危乳头状甲状腺癌远处转移复发的预测因素
World J Surg. 2025 Jan;49(1):117-123. doi: 10.1002/wjs.12289. Epub 2024 Aug 26.
2
Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation.固定 3.7GBq（100mCi）放射性碘残馀清除后，预测中危分化型甲状腺癌患者的列线图的开发。
Front Endocrinol (Lausanne). 2024 May 30;15:1361683. doi: 10.3389/fendo.2024.1361683. eCollection 2024.
本文引用的文献
1
Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.放射性碘治疗降低低甲状腺球蛋白水平的中危 PTC 复发率。
J Clin Endocrinol Metab. 2023 Jul 14;108(8):2033-2041. doi: 10.1210/clinem/dgad045.
2
Predictive Factors Indicative of Hemithyroidectomy and Close Follow-Up versus Bilateral Total Thyroidectomy for Aggressive Variants of Papillary Thyroid Cancer.甲状腺乳头状癌侵袭性变体行半甲状腺切除术及密切随访与双侧全甲状腺切除术的预测因素
Cancers (Basel). 2022 Jun 2;14(11):2757. doi: 10.3390/cancers14112757.
3
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.低危甲状腺癌患者的甲状腺切除术不伴放射性碘治疗。
N Engl J Med. 2022 Mar 10;386(10):923-932. doi: 10.1056/NEJMoa2111953.
4
Finding the Optimal Age Cutoff for the UICC/AJCC TNM Staging System in Patients with Papillary or Follicular Thyroid Cancer.探讨 UICC/AJCC TNM 分期系统中甲状腺乳头状癌或滤泡状癌最佳年龄截断点。
Thyroid. 2021 Jul;31(7):1041-1049. doi: 10.1089/thy.2020.0615. Epub 2021 Mar 4.
5
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南：美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
6
Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature.低风险分化型甲状腺癌与放射性碘残留消融：文献系统综述
J Clin Endocrinol Metab. 2015 May;100(5):1748-61. doi: 10.1210/jc.2014-3882. Epub 2015 Feb 13.
7
Thyroid cancer mortality and incidence: a global overview.甲状腺癌的死亡率和发病率：全球概述。
Int J Cancer. 2015 May 1;136(9):2187-95. doi: 10.1002/ijc.29251. Epub 2014 Oct 13.
8
Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients.低活性初始术后 131I 治疗后，高风险和低风险患者的分化型甲状腺癌长期生存均较差。
J Clin Endocrinol Metab. 2014 Dec;99(12):4487-96. doi: 10.1210/jc.2014-1631.
Zotero 插件